Council of the District of Columbia honors the Festival Artes de Cuba
The Council of the District of Columbia passed a resolution in which it acknowledges and honors the Festival Artes de Cuba, launched on May 8 at the John F. Kennedy Center for the Performing Arts, a prestigious institution based in the U.S. capital city.
The resolution was presented to the Ambassador of Cuba to the United States, José Ramón Cabañas, by representatives of the City Council in an event held at the Embassy of Cuba in Washington D.C. to honor the Festival Artes de Cuba, the largest of its kind to be held in the United States.
Festival Artes de Cuba launched in Washington D.C.
The Festival “Artes de Cuba: From the Island to the World” opened its doors on May 8 at the Eisenhower Theater of the prestigious John F. Kennedy Center for the Performing Arts, with an opening gala that evidenced the richness, diversity and artistic talent that identifies Cuba as a nation.
Representatives from Cuba and the United States talk about cooperation in agriculture
On April 10-11, 2018, a technical exchange was held in Washington D.C. between authorities from Cuba and the United States on the cooperation in the field of agriculture.
Ambassador of Cuba pays a working visit to Florida
The Ambassador of Cuba in Washington D.C., José Ramón Cabañas, paid a working visit to Florida on April 9- 10.
The high-ranking official had the opportunity to meet with businesspersons from several companies with contracts in Cuba, in particular, with those from the transportation sector, which in 2017, transported more than one million passengers to the Island from the United States.
Cuban and U.S. companies reached an agreement on Heperbrot-P
The Cuban company Heber Biotec and the U.S. company Mercurio Biotec join efforts to bring Heberprot-P therapy to patients who suffer from diabetic foot ulcer (DFU) in the United States, upon approval from the U.S. Food and Drug Administration (FDA).
According to the press note released by the entrepreneurial group BioCubaFarma, the Cuban therapy is expected to lower in more than half the current figure of risk of diabetic foot ulcer-related amputations in the United States, due to the successful history of the product and the commitment given by Mercurio and Heber.